Combined Treatment with Exenatide and Cyclosporine A or Parstatin 1-26 Results in Enhanced Reduction of Infarct Size in a Rabbit Model

Journal of Cardiovascular Pharmacology

Volumn 70, Issue 1, 2017, Pages 34-41

  Alexopoulos, Panagiotis ^a,b   Panoutsopoulou, Konstantina ^a   Vogiatzis, George ^c   Koletsis, Efstratios ^b   Dougenis, Dimitrios ^b   Tsopanoglou, Nikos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c GENESIS Pharma SA   (Greece)

Author keywords

combination therapy; cyclosporine A; exenatide; myocardial reperfusion injury; parstatin 1 26

Indexed keywords

CARDIOVASCULAR AGENT; CYCLOSPORIN A; EXENDIN 4; PARSTATIN 1 26; PROTECTIVE AGENT; PROTEIN INHIBITOR; SODIUM CHLORIDE; TROPONIN I; UNCLASSIFIED DRUG; CYCLOSPORINE; PAR-1 RECEPTOR (1-41), HUMAN; PEPTIDE; PEPTIDE FRAGMENT; PROTEINASE ACTIVATED RECEPTOR 1; VENOM;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HEART HEMODYNAMICS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE SIZE; HEART PROTECTION; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT MODEL; TREATMENT RESPONSE; ANIMAL; DISEASE MODEL; HEART INFARCTION; LEPORIDAE; PATHOLOGY;

ANIMALS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PEPTIDE FRAGMENTS; PEPTIDES; RABBITS; RECEPTOR, PAR-1; VENOMS;

EID: 85024486364     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000492     Document Type: Article

References (31)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121-1135.
2. Dominguez-Rodriguez A, Abreu-Gonzalez P. Cardioprotection and pharmacological therapies in acute myocardial infarction: challenges in the current era. World J Cardiol. 2014;6:100-106.
3. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post, and remote conditioning. Circ Res. 2015;116: 674-699.
4. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123:92-100.
5. Ferdinandy P, Hausenloy DJ, Heusch G, et al. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev. 2014;66:1142-1174.
6. Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013;34:1714-1724.
7. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243-249.
8. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501-510.
9. De Nicola M, Du J, Wang Z, et al. Stimulation of glucagon-like-peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium. Am J Physiol Endocrinol Metab. 2014;307:E630-E643.
10. Robinson E, Cassidy RS, Tate M, et al. Exendin-4 protects against postmyocardial infarction remodeling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol. 2015;110:20.
11. Alburquerque-Bejar JJ, Barba I, Inserte J, et al. Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs. Cardiovasc Res. 2015;107:246-254.
12. Tate M, Chong A, Robinson E, et al. Selective targeting of glucagonslike peptide-1 signaling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015;172:721-736.
13. Lonborg J, Vejistrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499.
14. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arteriol Thromb Vasc Biol. 2013;33:2252-2260.
15. Lønborg J, Kelbæk H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288-295.
16. Ong SB, Samangouei P, Kalkhoran SB, et al. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015;78:23-34.
17. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481.
18. Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015;373:1021-1031.
19. Zania P, Gourni D, Aplin AC, et al. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. J Pharmacol Exp Ther. 2009;328:378-389.
20. Routhu KV, Tsopanoglou NE, Strande JL. Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia-reperfusion injury. J Pharmacol Exp Ther. 2010;332:898-905.
21. Lecour S, Botker HE, Condorelli G, et al. ESC Working Group Cellular Biology of the Heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014;104: 399-411.
22. Morel O, Perret T, Delarche N, et al. Pharmacological approaches to reperfusion therapy. Cardiovasc Res. 2012;94:246-252.
23. Schmidt MR, Stottrup NB, Contractor H, et al. Remote ischemic preconditioning with-but not without-metabolic support protects the neonatal porcine heart against ischemia-reperfusion injury. Int J Cardiol. 2014; 170:388-393.
24. Yang XM, Cui L, Alhammouri A, et al. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013;27:403-412.
25. Ha SJ, Kim W, Woo JS, et al. Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol. 2012;32:474-480.
26. Cohen MV, Downey JM. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered. J Cardiovasc Pharmacol Ther. 2014;19:179-190.
27. Diamantopoulos A, Kyriazis I, Geronatsiou K, et al. Parstatin prevents renal injury following ischemia/reperfusion and radioconstrast administration. Am J Nephrol. 2012;36:278-286.
28. Eltzschig HK, Eckle T. Ischemia and reperfusion: from mechanism to translation. Nat Med. 2011;17:1391-1401.
29. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61:481-497.
30. Huang H, Vasilakis P, Zhong X, et al. Parstatin suppresses ocular neovascularization and inflammation. Invest Ophthalmol Vis Sci. 2010;51: 5825-5832.
31. Griffiths EJ, Halestrap AP. Protection by cyclosporine A of ischemia/ reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol. 1993;25:1461-1469.